Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polycythemia vera hematocrit target trial
ACTRN12609000046202Phase 3Recruiting
- Sponsor
- Consorzio Mario Negri Sud
- Start
- May 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxyurea and aspirin in polycythemia vera (PV) (2 arms), sponsored by Consorzio Mario Negri Sud. Primary endpoint: Composite of cardiovascular death plus thrombotic events. Started May 2008; status: recruiting.
02
Drugs
hydroxyureaaspirin
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on ACTRN12609000046202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000046202.